Vnitr Lek 2026, 72(6):382-387 | DOI: 10.36290/vnl.2026.071

Dyslipidemia in cardio-reno-metabolic syndrome

David Karásek
III. interní klinika - nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

Cardio-reno-metabolic (CRM) syndrome is a complex disease resulting from the interaction of metabolic disorders, cardiovascular impairment and chronic kidney disease. The basic pathogenetic mechanism is adipose tissue dysfunction leading to insulin resistance, chronic inflammation and vascular dysfunction. A typical laboratory manifestation is atherogenic dyslipidemia characterized by hypertriglyceridemia, reduced HDL-cholesterol and increased small dense LDL particles, often with only slightly increased LDL-cholesterol. Postprandial lipoproteins and residual cholesterol represent a significant cardiovascular risk. The basal therapy of dyslipidemia in CRM syndrome is focused on dietary measures aimed at weight loss and improvement of insulin sensitivity. Incretin analogue therapy plays an important role. If lipid target values are not achieved in this way, hypolipidemic drugs are indicated.

Keywords: cardio-reno-metabolic syndrome, type 2 diabetes, cardiovascular disease, chronic kidney disease, hypolipidemic drugs.

Accepted: September 15, 2026; Published: October 2, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D. Dyslipidemia in cardio-reno-metabolic syndrome. Vnitr Lek. 2026;72(6):382-387. doi: 10.36290/vnl.2026.071.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ndumele CE, Rangaswami J, Chow SL, et al.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 2023; 148:1606-1635. Go to original source...
    2. Godoy-Matos AF, Valério CM, Júnior WSS, et al. CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease. Diabetol Metab Syndr 2025; 17:218. Go to original source...
    3. Nzobokela J, Muchaili L, Mwambungu A, et al. Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome. Front Cardiovasc Med 2025; 12:1661563. Go to original source... Go to PubMed...
    4. Rosolová H, Piťha J, Freiberger T, et al. Kardio-reno-metabolický syndrom: stanovisko výboru České společnosti pro aterosklerózu - rok 2025. AtheroRev 2025; 10: 151-158.
    5. Ramakrishnan G, Arjuman A, Suneja S, et al. The association between insulin and low-density lipoprotein receptors. Diab Vasc Dis Res 2012; 9:196-204. Go to original source...
    6. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7:125-134. Go to original source... Go to PubMed...
    7. Karásek D. Diabetická dyslipidemie. Praha: Maxdorf, 2018. Jessenius. ISBN 978-80-7345-568-2.
    8. Wadström BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J 2023; 44:1432-1445. Go to original source...
    9. Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb. 2017; 24:95-109. Go to original source... Go to PubMed...
    10. Dallinga-Thie GM, Kroon J, Borén J, et al. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr Cardiol Rep. 2016; 18:67. Go to original source...
    11. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61:427-36. Go to original source... Go to PubMed...
    12. Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77:1439-1450. Go to original source... Go to PubMed...
    13. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44:4043-4140. Go to original source...
    14. Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocr Pract 2016; 22 Suppl 3:1-203. Go to original source... Go to PubMed...
    15. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391:541-551. Go to original source...
    16. Look AHEAD Research Group; Gregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016; 4:913-921. Go to original source...
    17. Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol 2023; 22:195. Go to original source... Go to PubMed...
    18. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(Supplement_1):S181-S206. Go to original source...
    19. Tornyos D, Meuer M, Lukács R, et al. Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. Front Cardiovasc Med 2022; 9:1041200. Go to original source...
    20. Sharma A, Verma S. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes 2020; 44:93-102. Go to original source... Go to PubMed...
    21. Skrobucha A, Pindlowski P, Krajewska N, et al. Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review. Front Cardiovasc 2024; 11:1446468. Go to original source... Go to PubMed...
    22. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9:653-662. Go to original source...
    23. Nicholls SJ, Pavo I, Bhatt DL, et al.; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025; 393:2409-2420. Go to original source... Go to PubMed...
    24. Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2 b Study. Diabetes Care 2021; 44:1433-1442. Go to original source...
    25. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023; 14:8289. Go to original source... Go to PubMed...
    26. Briand F, Augustin R, Wesche F, et al. Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet-Induced Obese Hamster Model. Diabetes 2024; 73 (Supplement_1): 1635-P. Go to original source...
    27. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402:529-544. Go to original source...
    28. Jastreboff AM, Kaplan LM, Frías JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023; 389:514-526. Go to original source...
    29. Mach F, Koskinas KC, Roeters van Lennep JE, et al.; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46:4359-4378. Go to original source... Go to PubMed...
    30. Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397-1405. Go to original source... Go to PubMed...
    31. Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125. Go to original source... Go to PubMed...
    32. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372:2387-2397. Go to original source...
    33. Giugliano RP, Cannon CP, Blazing MA, et al.; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137:1571-1582. Go to original source... Go to PubMed...
    34. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192. Go to original source...
    35. Singh A, Kesani H, Verma S, et al. Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management. Cureus 2025; 17:e94134. Go to original source...
    36. Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab 2019; 21:903-908. Go to original source... Go to PubMed...
    37. Imbalzano E, Ilardi F, Orlando L, et al. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2023; 9:318-327. Go to original source...
    38. Igweonu-Nwakile EO, Ali S, Paul S, et al. A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. Cureus 2022;14:e29140. Go to original source... Go to PubMed...
    39. Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab 2024; 26:3223-3237. Go to original source... Go to PubMed...
    40. Landmesser U, Ray KK, Raal FJ, et al.; ORION Investigators. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials. J Am Soc Nephrol 2026; doi: 10.1681/ASN.0000001006. Go to original source... Go to PubMed...
    41. Cao YX, Liu HH, Dong QT, et al. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20:1391-1398. Go to original source...
    42. Li F, Ye H, Chen L, et al. Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin. Front Pharmacol 2025; 16:1554631. Go to original source...
    43. Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388:1353-1364. Go to original source... Go to PubMed...
    44. Leiter LA, Banach M, Catapano AL, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 2022; 24:868-880. Go to original source... Go to PubMed...
    45. Ray KK, Bloedon L, Li N, Nissen SE; co-authors. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors' reply. Lancet Diabetes Endocrinol. 2024; 12:228-229. Go to original source...
    46. Stemmer K, Finan B, DiMarchi RD, et al. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Adv Drug Deliv Rev 2020; 159:34-53. Go to original source...
    47. O'Brien RC, Abdallah K, Dong X, et al. Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. J Diabetes 2026; 18:e70193. Go to original source... Go to PubMed...
    48. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.